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Abstract
Migration is a complex process that, besides its various physiological functions in embryogenesis and adult tis-
sues, plays a crucial role in cancer cell invasion and metastasis. The focus of this study is the involvement and
collaboration of Akt, focal adhesion kinase (FAK), and Src kinases in migration and invasiveness of colorectal can-
cer cells. We show that all three kinases can be found in one protein complex; nevertheless, the interaction be-
tween Akt and Src is indirect and mediated by FAK. Interestingly, induced Akt signaling causes an increase in
tyrosine phosphorylation of FAK, but this increase is attenuated by the Src inhibitor SU6656. We also show that
active Akt strongly stimulates cell migration, but this phenomenon is fully blocked by FAK knockdown or partly by
inhibition of Src kinase. In addition, we found that all three kinases were indispensable for the successful inva-
sion of colorectal cancer cells. Altogether, the presented data bring new insights into the mechanism how the
phosphatidylinositol-3-kinase (PI3-K)/Akt pathway can influence migration of colorectal adenocarcinoma cells. Be-
cause FAK is indispensable for cell movements and functions downstream of Akt, our results imply FAK kinase as
a potential key molecule during progression of tumors with active PI3-K/Akt signaling.
Translational Oncology (2009) 2, 281–290
Introduction
Cancer metastasis results from progression of a tumor in situ to an
invasive tumor involving the acquisition of cell motility mediated by
changes in the cytoskeleton, loss of cell-cell adhesion, and gain of cell-
matrix adhesion along with production and activation of extracellular
proteases [1]. Migration is a complex process encompassing changes
such as actin polymerization, membrane extension, turnover of focal
adhesions (FAs), and myosin activity during contractile force. Besides
its function in embryogenesis, inflammatory responses, wound repair,
and angiogenesis, it also plays a crucial role in cancer cell invasion and
metastasis [2].
Focal adhesions are sites of cell attachment to the extracellular ma-
trix (ECM) where transmembrane integrins link the ECM to the cyto-
skeleton [3]. Among the proteins localized to the FAs are, for example,
Src family kinases, FA kinase (FAK), p21-activated kinase (PAK), as
well as the scaffolding proteins paxillin and Ahs and the actin-binding
proteins vinculin and talin [4]. Dynamic turnover of FAs is critical for
cell growth, mitosis, migration, survival, and gene expression. The FAs
also become very important duringmetastasis formation.Without these
contacts, the cells die through the controlled process of cell death, called
anoikis [5].
FAK was originally identified as a nonreceptor protein tyrosine ki-
nase localized to the focal contact protein clusters. This enzyme has
been shown to facilitate generation of integrin-stimulated signals to
downstream targets such as extracellular signal–regulated kinase 2 or
c-Jun-N-terminal kinase [6]. Up-to-date, it has been reported that
activation of FAK leads to a number of processes, including cell
attachment, migration, chemotaxis, proliferation, and survival [7].
Most of all, FAK is involved in cell motility and protection against
apoptosis. Constitutively active FAK promotes survival of epithelial
cells in suspension, whereas cells derived from FAK-knockdown
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embryos exhibit reduced migration [8]. FAK has been found highly
expressed in a variety of tumors, including head and neck, ovarian,
thyroid, and colon carcinomas [9,10].
For cancer invasion and metastasis, two prerequisites are necessary
among others: first, a single cell must separate from the primary solid
tumor, which requires a loss of cell-cell adhesion [11], and second,
the invading cell needs to secrete matrix metalloproteinases (MMPs).
MMPs comprise a group of zinc-dependent ECM-degrading enzymes.
The increased expression of MMPs correlates well with the progres-
sion of various types of tumors [12,13]. Particularly, MMP-9 (gela-
tinase B/92-kDa type IV collagenase) is expressed in a large variety
of malignant cells, having collagen, a major component of the ECM
and basement membrane, as its main substrate [14,15].
Akt/protein kinase B is a core member of the phosphatidylinositol-
3-kinase (PI3-K) signaling pathway. On stimulation of the cell by var-
ious extracellular stimuli, Akt is recruited to the plasma membrane and
activated by the binding of its pleckstrin homology (PH) domain to
phosphatidylinositol-3-phosphate, the main product of PI3-K, in co-
operation with phosphoinositide-dependent protein. Activated Akt
has been reported to play important roles in cell proliferation, sur-
vival, insulin-stimulated glucose metabolism, chemotaxis, and angio-
genesis [16,17].
It has been known that FAK plays a dual role and mediates mul-
tiple signaling pathways by either phosphorylation or scaffolding.
FAK is targeted to growth factor receptors on the one hand and in-
tegrin receptors on the other (reviewed by van Nimwegen and van de
Water [7]). Whereas the survival signaling through the growth factor
receptors is triggered by the N-terminus of FAK, the FAK C-terminal
domain mediates proliferation and adhesion/migration signaling. In
the latter cases, FAK is activated through integrin receptors while it
becomes recruited to integrins by paxillin, vinculin, and talin. Al-
though it has been reported that, besides FAK, Akt may also play
a role in migration [18], it has not been elucidated whether there
is any connection between FAK and Akt in migration and/or inva-
sion of cancer cells.
The current article focuses on a putative collaboration of FAK, Src,
and Akt in the process of migration and invasion of colorectal can-
cer cells. We bring evidence that FAK and Akt act together in both
processes. We prove that all three kinases are found inside the cells
in one supramolecular complex. We also show that FAK is a down-
stream target for Akt and that the Akt-induced phosphorylation of
FAK partly depends on Src. Ectopic Akt accelerates cell migration,
but inhibition of Src by a specific inhibitor partially prevents this ac-
celeration. Experiments using knockdowns of FAK by short hairpin
RNA (shRNA) clearly indicate that FAK is a crucial kinase for the
migration of colorectal cells; moreover, it possibly integrates inputs
from both Akt and Src kinases. Finally, we have found that FAK,
Akt, and Src are indispensable for the successful onset of invasion
in colorectal cancer cells.
Materials and Methods
All general reagents were obtained from Sigma (Prague, Czech Re-
public) unless otherwise posted. Protein G-Sepharose 4 Fast Glow
was purchased from Amersham Biosciences (Vienna, Austria), Fugene
was from Roche (Prague, Czech Republic), 4-OH-hydroxytamoxifen
(HXT) was from Sigma, and puromycin and G418 were from Alexis
(Farmingdale, NY). Anti-Akt, anti–phospho-Ser473 Akt, and anti–
phospho-Y397 FAK rabbit polyclonal antibodies were obtained from
Abcam (Cambridge, UK), and anti–phospho-Y925 FAK rabbit poly-
clonal antibody was from Cell Signaling Technology (Danvers, MA).
Anti-FAK antibody was either prepared in our laboratory (rabbit poly-
clonal; see below) or purchased from BD Transduction Laboratories
(Franklin Lakes, NJ) (mouse monoclonal). The anti-Src antibody
LA074 and antitubulin antibodies were described by Vojtechova et al.
[19]. All Alexa-conjugated secondary antibodies were purchased from
Molecular Probes (Eugene, OR). The AktIV and SU6656 inhibitors
were obtained from Calbiochem (MERCK, Prague, Czech Republic),
and wortmannin was from Sigma.
Cell Culture
Human colorectal adenocarcinoma cells DLD-1,HT29, and SW620
were grown in Dulbecco’s modified Eagle’s culture medium (DMEM)
including 10% fetal calf serum and antibiotics. For experiments using
inhibitors, cells were first starved overnight with 2% serum DMEM,
and then the medium was changed for 10% serum DMEM supple-
mented either with DMSO as a vehicle or given inhibitors.
Viral Constructs
FAK shRNA constructs. The empty lentiviral vector GIPZ and
expression cassettes encoding five different shRNA for FAK were pur-
chased fromOpen Biosystems (Huntsville, AL). These vectors were des-
ignated as follows: #1 (catalog no. V2LHS_57326), #2 (catalog no.
V2LHS_57328), #3 (catalog no. V2LHS_57330), #4 (catalog no.
V2LHS_248542), and #5 (catalog no. V2LHS_248262). Functional
virions were prepared according to the manufacturer’s instructions.
Vector GIPZ/shRNA constructs, the packaging construct psPAX, and
the envelope construct pMD2G were transfected with Fugene in the
ratio 3:2:1, respectively, into 293 FT cells (Invitrogen, Carlsbad, CA).
The conditioned media containing viral particles were collected after
24 and 48 hours, pooled, and used for infection of DLD-1, HT29,
and SW620 cells.
Inducible Akt adenoviral constructs. We used a recombinant ade-
novirus expressing the estrogen-dependent inducible form of human
Akt-1 (iAkt [20]). This construct encodes Akt protein lacking its PH
domain with myristoylation signal fused to the N-terminus. The ec-
topic iAkt protein is expressed, but its enzymatic activity is induced
only in the presence of HXT [21].
Src kinase mutants. The retroviral constructs for the constitutively
active v-Src (pH19KE) and the Src kinase-dead double Y416F-K295N
mutant (pLmSRN) were prepared in the pLXRN retroviral vector as
described previously [19]. The empty vector pLXRN, viral constructs
pH19KE and pLmSRN, the packaging construct psPAX, and the en-
velope construct pMD2G were transfected with Fugene in the ratio
3:2:1, respectively, into 293 FT cells. The conditioned media with
viral particles were collected after 24 and 48 hours, pooled, and sub-
sequently used for infection of DLD-1 and HT29 cells.
PTEN Small Interfering RNA Transfections
For small interfering RNA (siRNA)–mediated knockdowns, human
PTEN siRNA (sc-29459) or control nonsilencing siRNA (sc-37007)
were purchased from Santa Cruz Biotechnology and transfected into
target cells using a siRNA transfection kit (Santa Cruz Biotechnology,
Heidelberg, Germany).
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Infections
FAK shRNA. The particular cells were infected at 70% confluence
with a viral suspension diluted with growth medium for 5 hours.
Then, the media were changed for fresh growth media, and the infec-
tants were cultured for another 48 hours. Subsequently, puromycin
selection (5 μg/ml final concentration) was done, and stable clones
were produced.
iAkt. The cells at 70%confluencewere coinfectedwith equal amounts
of two recombinant adenoviruses, one encoding a tetracycline-inhibited
transactivator, and the other a tetracycline-inhibited transactivator–
regulated gene expressing HXT-inducible HA-tagged membrane-
targeted Akt as described [20].
Src. The subconfluent cells were incubated with a mix of viral sus-
pension and polybrene for 60 minutes at room temperature, and
then fresh growth medium was added and the cells were incubated
for another 48 hours at 37°C. Subsequently, selection with G418 at a
concentration of 400 μg/ml was performed and several stable clones
were prepared.
Ectopic Akt Induction and Kinase Inhibitor Treatment
After infection with iAkt constructs, the cells were grown until
their confluence and were then incubated in growth medium con-
taining 1 μM HXT. After 12 hours of pretreatment, the cells were
incubated again with HXT plus either a vehicle (DMSO) or 5 μM
SU6656 or 500 nM AktIV for another day. In case of a longer incu-
bation period (migration assays), medium with inhibitors was changed
every day.
Western Blot Analysis and Immunoprecipitations
The cells were lysed in ice-cold extraction buffer [40 mM β-
glycerophosphate, 50 mM HEPES pH 7.4, 5 mM EGTA, 1 mM
Na3VO4, 1 mM benzamidine, 3 mM Na4P2O7, 0.5 mM PMSF,
1% Triton X-100, and the proteinase inhibitors pepstatin, antipain,
and leupeptin (0.4 μg/ml each; all purchased from Pierce, Thermo
Fisher Scientific, Rockford, IL)] unless otherwise indicated. Cell debris
was pelleted by centrifugation at 20,000g for 5 minutes, and super-
natants were frozen until further use.
FAK Antibody Production
Antiserum to FAK was produced by immunization of rabbits with
bacterially expressed C-terminal fragment FAT (aa 864-1005) of hu-
man FAK. The antiserum was then antigen-purified [22] and used
for immunohistochemistry and Western blot analysis.
Immunocytochemistry
Cells cultured on slides were fixed and stained as described [20]
using appropriate primary antibodies and Alexa 594– or Alexa
488–conjugated secondary antibodies.
CellTiter-Blue Assay
The CellTiter-Blue Cell Viability Assay Kit from Promega was
used to estimate the total metabolism rate and the number of viable
cells after treatment of colorectal cancer cells with Akt or Src in-
hibitors. DLD-1, HT29, and SW620 cells were plated in triplicates
onto black 96-well plates at three different densities and let grow
for 24 hours (DLD-1 and SW620 cells) or 48 hours (HT29 cells)
according to their known doubling times. After that, the cells were
washed and starved in medium containing 2% serum. Subsequently,
the cells were incubated for 3 hours with complete growth me-
dium in the absence or presence of AktIV or SU 6656 inhibitors.
Then, the medium was changed for the medium containing resazurin
(ratio, 5:1); the cells were incubated for another 3 hours and measured
for fluorescence values shift with a fluorimeter EnVision (Perkin Elmer,
Waltham, MA).
Migration Scratch Assay
Cells were plated onto different culture vessels, and when conflu-
ent, the cell monolayer was wounded by manual scratching with a
pipette tip, washed with PBS, and incubated in complete growth
medium in the absence or presence of inhibitors or HXT for appro-
priate periods. Matched paired marked regions were photographed
every 24 hours.
MMP in-Gel Zymography
Parental DLD-1, HT29, and SW620 cells or their FAK-specific
shRNA-expressing clones were used for this assay. SW620/GIPZ or
SW620shFAK#5 cells were subsequently either starved and treated
with different inhibitors or infected with the adenoviral construct en-
coding iAkt. All the infected cells were then serum-deprived overnight
before serum addition and incubation with or without Src inhibitor
SU6656 and HXT for iAkt activation. Samples of conditioned medium
were analyzed for proteinase activity by substrate-gel zymography as
described previously [23]. Briefly, equal amounts of total protein from
experimental samples were resolved on 8% SDS–polyacryalmide gels
containing 0.1% gelatin. After electrophoresis, gels were washed with
2.5% Triton X-100 for 30 minutes at room temperature and then in-
cubated with substrate buffer (50 mMTris, 0.2 MNaCl, 5 mMCaCl2,
and 0.02% Brij, pH 7.6) overnight at room temperature. MMP-2 and
MMP-9 activities are represented by clear bands in a Coomassie blue–
stained gel.
In Vitro Invasion Assay
Cells were serum-starved for 24 hours and then split and plated
onto serum-free medium-rehydrated Matrigel-coated BD Biocoat in-
vasion or control chambers (Becton Dickinson, Franklin Lakes, NJ;
pore size, 8 μm) and allowed to spread on the membrane. After that,
the cells were incubated in serum-free medium with or without Akt
or Src inhibitors and let invade through the Matrigel or control in-
serts against 10% serum medium for 36 hours. Noninvading cells were
removed from the top of the inserts with a cotton swab; the mem-
branes were cut out, fixed, stained with hematoxylin, and mounted.
Each experiment was performed in duplicate. At least 10 fields per
filter were counted in each experiment.
Results
Akt, FAK, and Src Are Involved in Migration of Colorectal
Cancer Cells
According to the results shown in Figure 1A, inhibition of Akt,
Src, and PI3 kinase by their specific inhibitors in DLD-1 cells caused
a significant decrease in cell migration observed in all cases after a
3-day treatment of the cells with the inhibitors. For these experi-
ments, DLD-1, SW620, and HT29 human colorectal cancer cell
lines were used, and similar results were obtained for all of them.
Along with the results in Figure 1A comes the finding that Rac-1,
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one of the markers of the migrating cells [24,25], was localized into
the leading edges of the cells, whereas it completely disappeared from
that location in the cells treated with the Akt inhibitor IV (Figure 1B).
The same situation occurred when the cells were treated with the Src
inhibitor SU6656 as well as when the experiments were performed
with the cells lacking FAK (data not shown). To see whether the
inhibitors do not interfere with the proliferation status of the cells,
immunohistochemical staining was used with antibody against pro-
liferating cell nuclear antigen (PCNA), one of the markers expressed
in proliferating cells [26]. It seemed that neither of the inhibitors sig-
nificantly altered PCNA expression in the treated cells. Representative
pictures are shown in Figure 1B.
We have transduced three human colorectal cancer lines with five
different lentiviral constructs expressing shRNA specific to FAK or
with GIPZ lentivirus containing a sequence for control nonsilencing
shRNA (further indicated as GIPZ cells). We have obtained three
successful clones of each cell line where FAK levels were substantially
downregulated (Figure 2A). The cells producing shRNA #3 and #5
(these cells were named shFAK#3 and shFAK#5, respectively) were
used subsequently in further experiments. In accordance with previ-
ous literature data [27], migration of DLD-1 cells with downregu-
lated FAK was invincibly blocked 3 days after scratching compared
with uninfected cells or cells expressing nonsilencing shRNA from
the GIPZ vector (Figure 2B). The same dependence of migration
on the expression levels of FAK was observed in clones #3 and #5
of HT29 and SW620 cells (data not shown). In the next set of ex-
periments, we detected total FAK, Akt, and Src, or FAK phosphor-
ylated at Y397, Akt phosphorylated at S473, or Src phosphorylated
at Y416. All these modifications indicate the activity status of the
respective kinase [18,28,29]. It is clear that the lack of FAK did
not change either expression or phosphorylation of Akt or Src (Fig-
ure 2C ). We have also produced clones of DLD-1 and HT29 cells
expressing either empty vector pLXRN or complementary DNA for
the active wild-type v-Src (pH19KE) or the kinase-dead version of
v-Src mutated in two phosphorylation sites necessary for full Src ki-
nase function activation (pLmSRN [19]). Figure 2D shows a West-
ern blot that was done to see the correlation between Src, FAK, and
Akt in the clones with ectopic Src. It is clear that Src phosphorylation
was attenuated in the cells expressing kinase-dead Src. Moreover,
with reduced Src activity, both Akt and FAK phosphorylation also
decreased. This finding is in agreement with the published data
[30] and confirms assumptions that the FAK function depends on
the Src presence in the process of migration. Phosphorylation of Akt
in the cells with diminished Src activity seemed decreased as well. Con-
versely, cells with ectopic wild-type Src showed an increase in Akt
and FAK phosphorylation (Figure 2D). These results correspond well
with our recent finding that, in hamster fibroblasts, Akt can be regu-
lated by Src [19]. The phenomenon found in DLD-1 cells was also
observed in HT29 cells overexpressing wild-type Src and the kinase-
dead Src mutant (data not shown). As seen in Figure 2E , migration
of DLD-1 cells expressing inactive Src displayed significant inhibition
of migration 3 days after scratching compared with that of the cells
expressing an empty vector or the active form of v-Src. This outcome
complements well the observation described previously when the cells
were treated with the Src inhibitor SU6656 (Figure 1A). Altogether,
these data indicated the crucial and previously characterized [31] role
of Src in cellular migration.
To exclude the possibility that the migratory defects of the inhibitor-
treated or shRNA-expressing cells are caused indirectly by decreased
cell proliferation and survival, we performed two different experiments.
First, DLD-1, SW620, and HT29 cells selected for the presence of
GIPZ control vector or shRNA to FAK were used for the CellTiter-
Blue assay (for details, see the Materials and Methods section). The
cells at given densities were starved overnight and subsequently in-
cubated in the complete growth medium for 3 hours (Table 1). Then,
the cells were incubated in the presence of resazurin in the culture
Figure 1. Inhibitors of Akt, Src and PI3 kinase block migration of colorectal cancer cells. (A) DLD-1 cells were scratched and incubated
for additional 3 days in the absence or presence of 500 nM Akt inhibitor IV, 5 μM Src inhibitor SU6656 and 100 nM PI3 kinase inhibitor
wortmannin. (B) Intracellular localization of PCNA (green) or Rac-1 (red) in the scratched DLD-1 cells treated either with the vehicle or
with the Akt inhibitor IV. Arrowheads point to Rac-1 localized to the leading edges and lamellipodia of the migrating cells. The images are
representative of three independent sets of experiments.
284 Function of FAK and Akt1 in Migration and Invasion Turečková et al. Translational Oncology Vol. 2, No. 4, 2009
media. Based on the emission fluorescence shift measured, cells trans-
duced with FAK-specific shRNA exhibited a tendency to a higher
metabolic rate when compared with GIPZ cells. Table 1 also shows
comparison of live cell counts of expressing DLD-1, SW620, or HT29
cells GIPZ or shFAK#5 counted either at the time of changing the
low-serum medium for the complete one (T 0) or after an additional
24-hour incubation (T 24). According to this comparison, FAK deple-
tion resulted in no cell death. Instead, it promoted a slight increase in
the proliferation rate (Table 1).
FAK Is Essential for Akt-Dependent Cell Migration
Because Akt and FAK are involved in the migration process of colo-
rectal cancer cells, we asked next whether activation of Akt kinase
could affect phosphorylation of FAK and/or cell migratory proper-
ties. First, using siRNA, we downregulated the expression of PTEN,
a negative regulator of the PI3/Akt signaling pathway. As shown in
Figure 2. FAK and Src are necessary for migration of DLD-1 cells. (A) Western blot analysis of FAK expression levels in the indicated cell
lines transduced either with the GIPZ lentiviral vector containing control nonsilencing shRNA or with five different lentiviruses encoding
FAK-specific shRNA (#1-#5). As a loading control, α-tubulin expression was detected. (B) Comparison of migration in scratched parental
DLD-1 cells or cells transduced with the GIPZ vector (DLD/GIPZ) or with FAK-shRNA #3 and #5 (DLDshFAK#3 and DLDshFAK#5, re-
spectively). (C) Western blots comparing expression of FAK and FAK phosphorylated at Y397, Akt and Akt phosphorylated at S473, and
Src and phosphorylated Src (Y416) in DLD/GIPZ and DLDshFAK#3 and #5 cells, respectively. (D) Western blot detecting the presence of
c-Src, total Akt, or FAK proteins. The phosphorylation level of the proteins is compared, too. Cell lysates were prepared from cells trans-
duced with an empty vector (pLXRN), activated Src (pH19KE), or kinase-dead form of Src (pLmSRN) as labeled. α-Tubulin expression was
used as a loading control. (E) Comparison of migrating DLD-1 cells expressing the indicated Src constructs 3 days after scratching. The
images are representative of three independent experiments.
Table 1. Viability and Proliferation Rate of GIPZ or shFAK#5 Cells.
CellTiter-Blue (%) Live Cell Counts (%)
T0 T24
GIPZ DLD 100 ± 1.2 100 ± 8.6 98 ± 8.3
SW620 100 ± 3.2 100 ± 2.4 99 ± 6.6
HT29 100 ± 1.8 100 ± 3.7 95 ± 7.5
shFAK#5 DLD 118 ± 3.0 124 ± 4.2 128 ± 8.1
SW620 113 ± 5.6 125 ± 5.2 129 ± 7.8
HT29 114 ± 6.8 127 ± 4.4 131 ± 5.3
The proliferation status in colorectal cancer cells expressing GIPZ or shFAK#5. The left column
refers to the CellTiter-Blue assay results comparing total cell metabolism rates and viability. The
relative percentage figures are based on comparison of the average values of emission fluorescence
measured at 590 nm; the 100% count was attributed to the control GIPZ-expressing cells. The
two right columns compare cell counts of living cells obtained either at the time of changing the
low-serum starving medium for the complete one (T0) or after an additional 24-hour incubation
(T24). The cell counts of the control GIPZ-expressing cells were taken as 100%. The experiments
were done three times in triplicates, and SD values are also given.
Translational Oncology Vol. 2, No. 4, 2009 Function of FAK and Akt1 in Migration and Invasion Turečková et al. 285
Figure 3A, on the PTEN knockdown, phosphorylation levels of Akt
substantially increased. Interestingly, PTEN silencing also enhanced
FAK phosphorylation both at Y397 and at Y925 (Figure 3A). Western
blots in Figure 3B display the phosphorylation status of FAK, Akt, and
Src after treatment of the cells with Akt, Src, and PI3 kinase inhibitors.
Interestingly, all three inhibitors eliminated FAK phosphorylation at
both tyrosines. In addition, the Src inhibitor attenuated phosphoryla-
tion of Akt only partially. Yet, neither AktIV nor wortmannin blocked
Src phosphorylation (Figure 3B). In further experiments, the clones
of DLD-1 and HT29 cells expressing nonsilencing or FAK-specific
shRNA were infected with a recombinant adenovirus bearing a se-
quence for the hydroxytamoxifen (HXT)-inducible HA-tagged
membrane-targeted Akt-1 [20]. This ectopic myristoylated and PH
domain–deleted Akt-1 (iAkt) does not need the function of PI3
kinase, otherwise the upstream regulator for its activity [18,20]. In
the infected cells, iAkt protein is always expressed, but its full en-
zymatic activity requires the presence of HXT [21]. As expected, on
the treatment of DLD/GIPZ, DLDshFAK#5 with HXT, iAkt was
phosphorylated at Ser473 (Figure 3C and data not shown). Addition
of the Src kinase inhibitor SU6656 did not change the level of phos-
phorylation of endogenous or ectopic Akt kinase. However, induction
of iAkt was accompanied by an approximately 50% increase of phos-
phorylation of FAK in the DLD/GIPZ control cells (densitometric
data not shown). Interestingly, this increase was suppressed by Src in-
Figure 3. FAK functions downstream of Akt. (A) Western blots comparing protein expression levels of FAK and FAK phosphorylated
at Y397 (P-FAK) or at Y925 (Y925-FAK) in DLD-1 cells transfected with control nonsilencing siRNA or with siRNA specific to PTEN.
(B) Phosphorylation of FAK, Akt, and Src in DLD-1 cells treated with inhibitors. Besides antibodies against FAK phosphorylated at its
Y397 and Y925, also antibodies against Akt and Src phosphorylated at S473 and Y416, respectively, were used. For experiments dis-
played in panels C to E, DLD/GIPZ or DLDshFAK#5 cells were infected with the adenoviral construct encoding inducible iAkt. Subse-
quently, the cells were scratched and incubated in the absence or presence of iAkt-activating 4-hydroxytamoxifen (HXT) or the Src
specific inhibitor SU6656 as indicated. (C) Western blot showing protein levels of endogenous (endo) and ectopic (ecto) Akt and Akt
phosphorylation; the blots were further probed with anti-FAK and anti–phospho-FAK specific antibodies. α-Tubulin was used as a load-
ing control. Also shown are microscopic images of DLD/GIPZ control cells (D) and DLDshFAK#5 cells (E) after 3 days of migration under
the assigned conditions. All pictures represent two (A) or three (B–E) independent sets of experiments.
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hibition (Figure 3C). For obvious reasons, the phosphorylation status
of FAK could not be monitored in the cells expressing FAK-specific
shRNA. Furthermore, as shown in Figure 3D, whereas the HXT-
stimulated iAkt accelerated cell migration in the DLD/GIPZ cells,
the treatment with the Src inhibitor partly attenuated this acceleration.
Surprisingly, when the DLDshFAK#5 cells were infected and treated
the same way (Figure 3E), HXT-induced iAkt did not overcome the
lack of FAK. Moreover, when the latter cells were treated with
SU6656, their migration was stopped completely (Figure 3E). Similar
results were also obtained with HT29 cells (data not shown). It is
important to note that migration rates of all tested cells shown in
Figures 1 to 3 were always kept similar when observed at earlier time
points than 3 days after scratching (data not shown).
To find out whether FAK associates with endogenous Akt, a series
of coimmunoprecipitation experiments were done (Figure 4). These
results show that Akt indeed coimmunoprecipitated with FAK in
control DLD/GIPZ cells; furthermore, reduced intracellular levels of
FAK in DLDshFAK#3 and #5 cells, respectively, were clearly indicated
by the virtual absence of FAK in the anti-Akt precipitate. A simi-
lar situation was observed in the lysates of the same cells precipitated
with the Src antibody. Interestingly, almost no Src could be coimmuno-
precipitated with Akt in the cells lacking FAK (Figure 4). Experi-
ments performed with HT29 cells provided similar outcomes (data
not shown). These results suggest that all three molecules are present
together in one complex and that association between Src and Akt
might be FAK-dependent. Coimmunoprecipitations performed with
lysates of the cells treated with wortmannin did not show any altera-
tions in the mentioned complexes (data not shown).
MMP-9 Activity Depends on FAK Kinase Levels in Colorectal
Cancer Cells
Knowing that FAK, Src, and Akt are all required for successful
migration of colorectal cancer cells, we were interested whether the ki-
nases play a role in the invasiveness of these cells. For these experiments,
we used Matrigel-coated membrane inserts. Matrigel is a standard
chemically defined culture medium consisting of an essential protein
spectrum of the ECM and a basement membrane [32], so it provides
an optimal environment for selecting invasive from noninvasive cells.
Only those cells were stained and counted which invaded through
the Matrigel layer and the porous membrane underneath. The results
of this assay revealed that the lack of FAK in DLD-1 and SW620 cells
caused a significant reduction (P < .001) in the number of invading cells
compared with that of DLD/GIPZ or SW620/GIPZ cells (Figure 5, A
and B). Further, Matrigel assays were performed with the DLD-1 and
SW620 cells treated with either a vehicle (DMSO) or AktIV and
SU6656 inhibitors or wortmannin (Figure 5C ). The results confirmed
fundamental inhibition of the invasive features by inactivation of Src.
Akt and PI3 kinase seem to play a role in cell invasion as well because
the specific Akt inhibitor and wortmannin caused a significant decrease
in the invasive abilities of DLD-1 cells (P < .001; Figure 5C).
To understand the molecular background of the invasiveness of
colorectal cancer cells, we next performed experiments focusing on
the regulation of activity of MMP-9, one of the crucial enzymes par-
ticipating in ECM breakdown during metastasis formation [33]. Fig-
ure 6A represents several in-gel zymography assays performed with
conditioned culture media of different colorectal cell lines. FHC and
HT29 cells were used as references for the assays because FHC cells
were originally derived from normal colonic epithelia [34] and HT29
cells exhibit the lowest level of tumorigenicity of all cancer cell lines
chosen for these experiments [35]. SW620 cells originate from a dis-
tant metastasis of a colorectal cancer patient [36]. Because these cells
possess a higher activity of MMP-9, they were used as a positive con-
trol for Matrigel invasiveness and MMP-9 activity (Figures 5 and 6A).
MMP-2 was included as a loading control because its activity seemed
stable in various colorectal cells (Figure 6A and data not shown).
Figure 6B compares the activity of MMP-9 in SW620/GIPZ versus
SW620shFAK#5 cells treated with a vehicle (DMSO) or with AktIV
and SU6656 inhibitors or with wortmannin. Importantly, all three in-
hibitors lead to decreased MMP-9 activity compared with that of the
untreated cells (P < .001 for AktIV and wortmannin). For the last set
of experiments, SW620/GIPZ or SW620shFAK#5 cells were subse-
quently infected with the adenoviral construct encoding iAkt, and
the MMP-9/MMP-2 zymography assay was done with their condi-
tioned culture media (Figure 6B). For this experiment, the cells were
either treated or untreated with HXT in the absence or presence of
SU6656. Whereas induction of the ectopic iAkt in the SW620/GIPZ
cells did not alter the MMP-9 activity, the Src inhibitor decreased it
significantly. Also, the cells lacking FAK displayed lowered MMP-9
activity (60% decrease compared with the SW620 control). Further-
more, the treatment of these cells with the Src inhibitor or HXT did
not have any additional effect on MMP-9 in SW620shFAK#5 cells
(Figure 6B). Importantly, both untreated and treated SW620shFAK#5
displayed the same metabolic and proliferation rate and the MMP-2
activity as control SW620/GIPZ cells (Table 1, Figure 6, and data
not shown). In addition, the cells lacking FAK displayed significantly
Figure 4. FAK is in complex with Src and Akt. Lysates of DLD/GIPZ
cells or DLDshFAK#3 and #5 were immunoprecipitated with anti-
bodies against FAK, Src, and Akt (IP column on the left) and probed
for FAK, Src, or Akt on Western blots (WB column on the right). In
the column denoted LB, a lysis buffer without cell lysate was pre-
cipitated; in the column denoted lys, 10% of the total cell lysate of
the DLD/GIPZ cells were loaded. Staining with the anti-Akt and anti-
Src antibodies was performed sequentially on the same blot; there-
fore, the residual Akt signal from the first detection is still visible on
the membrane reprobed with the antibody against Src (first panel
from the bottom). The asterisk indicates heavy chains of immuno-
globulins. The collage represents two independent experiments.
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reduced MMP-9 activity compared with that of SW620/GIPZ cells
even in the absence of any inhibitors (Figure 6, B and C ).
Discussion
We have confirmed that all three kinases are involved in the mi-
gration of colorectal cancer cells because specific inhibitors for Akt,
Src, and PI3 kinase and shRNA for FAK blocked cell motility
(Figure 1). The FAK protein in DLD-1, SW620, and HT29 cells
expressing FAK-specific shRNA was almost completely ablated. In-
terestingly, these cells exhibited similar features as FAK−/− embry-
onic fibroblasts generated by Ilic et al. [8], which display severe
migration defects but do not show any proliferative discrepancies.
Colorectal cancer cells with downregulated FAK exhibited some
additional significant morphologic and physiological changes com-
pared with the control cells. They became extremely adherent to
the culture vessel surface and they had a tendency to stay in clusters
on cell division. In addition, the cells exhibited slightly higher pro-
liferation and metabolic rate irrespective of the Src or Akt inhibi-
tor treatment (Table 1). Although lack of FAK has been reported
to promote apoptosis in certain cell types [37,38], the rate of cell
death did not increase in shFAK cells compared with that of GIPZ
control cells. On the basis of these findings, we concluded that the
observed inhibition of cell migration was not just an outcome of in-
creased cell death or decreased proliferation rate of cells used for
the scratch assay. In the cells with a migratory defect, Rac-1 was re-
tracted from the leading edges and lamellipodia while it did not
change its overall intracellular levels (Figure 1B and data not shown).
Because Rac-1 represents a molecule stimulating reorganization of
the cortical cytoskeleton at the membrane before cell spreading
and movement [24], this change of the Rac-1 intracellular locali-
zation indicates the impairment of these processes in the cells lack-
ing FAK. This observation also implies Rac-1 as the appropriate
molecular marker to follow changes in colorectal cancer cell migra-
tion. The fact that membrane ruffles are still seen despite treatment
with AktIV inhibitor can be explained by findings of Higuchi et al.
[39], who proved that dominant-negative Akt inhibits cell motility
without affecting ruffling membrane-type actin reorganization. The re-
sults with the Src and Akt inhibitors agreed with the previous literature
data on the function of both kinases in migration [27,31]. We have
further shown that whereas the ectopic wild-type Src increases cell
migration, its dominant-negative variant slowed down the cell move-
ment in the scratch assays (Figure 2E). Moreover, the active Src pro-
moted phosphorylation of Akt and FAK, whereas the kinase-dead Src
inhibited this phosphorylation (Figure 2D). The latter results are in
agreement with our previous findings that, in hamster fibroblasts, Src
functions upstream of Akt [19].
Surprisingly, the following two experiments indicated that, al-
though Src is indeed an important kinase in respect to the phos-
phorylation status of FAK, Akt also plays a role. First, the activation
of endogenous Akt by knockdown of PTEN resulted in increased
phospho-FAK levels (Figure 3A). Second, cells with iAkt induced by
HXT displayed increased FAK phosphorylation (Figure 3B). Interest-
ingly, the phosphorylation levels of FAK dropped down when the cells
were treated simultaneously with HXT and Src inhibitor SU6656;
nevertheless, SU6656 had no effect on the phosphorylation of both
endogenous and ectopic Akt (Figure 3B). Together with the proof that
all three kinases exist in one complex (Figure 4), these data suggest
that Akt functions upstream of FAK but its effect is, to some extent,
mediated by Src. In addition, FAK functioning downstream of Akt
or Src was also suggested by our data revealing that there is no nega-
tive feedback effect of silencing FAK expression on the expression or
phosphorylation of either Akt or Src (Figure 2C ).
The notion that Akt needs to be supported by Src during cell mi-
gration was supported by the results of the scratch migration assays
that showed partial attenuation of iAkt-driven migration by treat-
Figure 5. FAK, Src, and Akt play roles in colorectal cancer cell inva-
sion. (A) Indicated cells were starved and plated at the same densi-
ties on Matrigel-coated culture insert membranes and subsequently
let penetrate through toward serum in the culture medium for
36 hours. Then, the invaded cells were fixed, stained, and counted.
(B) Histogram comparing the resulting counts of the invaded unin-
fected SW620 cells, SW620/GIPZ, DLD/GIPZ, and SW620shFAK or
DLDshFAK#3 or #5, respectively. (C) Counts of invaded SW620 or
DLD-1 cells treated with a vehicle (DMSO), AktIV inhibitor, Src inhib-
itor SU6656, or PI3 kinase inhibitor wortmannin. Data in histograms
in panels B and C show statistical differences (n = 3 for each) in the
penetrated cell counts of either shFAKclonesor the cells treatedwith
the given inhibitors normalized to their relevant controls (i.e., either
GIPZ- or DMSO-treated). *P < .01; **P < .001.
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ment with the Src inhibitor (Figure 3D). However, all migration ex-
periments confirmed the indispensability of FAK for cell movement
(Figures 2B and 3E ). Although the increase in FAK phosphorylation
(at its Y397) in cells with the HXT-induced iAkt was rather moder-
ate, the migratory response was robust. Hence, we hypothesize that
FAK might be phosphorylated (and thus activated) either directly by
Akt or there is additional positive feedback to some other factors
coming down from the Akt-activated FAK. Unfortunately, until
now, we could not address the putative direct interaction between
Akt and FAK by an in vitro enzyme activity assay because of the lack
of any defined FAK-specific substrate. In addition, in vivo [ 32P] ortho-
phosphate labeling of FAK would not bring clear data owing to the
presence of other labeled kinases (especially Src) in the anti-FAK pre-
cipitates obtained from the 32P-labeled cells.
The last set of experiments was done to find out whether FAK
might be a potential stimulator of colorectal cancer cell invasiveness.
In colorectal cancer, the expression of FAK is increased irrespective of
tumor grading compared with normal colonic mucosa [7]. In addi-
tion, many other malignant human tumor samples exhibit increased
FAK expression and tyrosine phosphorylation [9]. Hsia et al. [40]
showed that FAK−/− embryonic fibroblasts displayed disability to
promote activation of MMP-9 protein, which stands for one of the
most common markers of invasive potential. In addition, expression
of cytoplasmic active forms of MMP-7 and MMP-9 was detected in
more than 50% of samples from human colorectal cancer patients
[23]. Therefore, knowing the mutual function of FAK and Akt in
migration and considering migration as a prerequisite for invasive-
ness, we tested a potential collaboration of the two kinases in inva-
sion assays. The outcome of the experiments done with cells either
lacking FAK or treated with Akt, Src, or PI3 kinase inhibitors on
cultured Matrigel (Figure 5) revealed that both FAK and Akt kinases
(plus PI3 kinase) are indispensable for successful onset of invasion in
colorectal cancer cells. According to our results (Figure 6B), the in-
vasive features of colorectal cancer cells might involve FAK-, Akt-,
Src-, and PI3 kinase–dependent enzymatic activation of MMP-9.
However, whereas AktIV inhibitor blocks activity of all Akt isoforms,
the adenoviral construct we used in our experiments (including that
shown in Figure 6C ) was designed for Akt-1 expression only. On the
basis of the latter facts, it seems that contrary to FAK and Src, the
Akt-1 isoform is not involved in the regulation of MMP-9 activity.
The present study brings new data on the cooperation of Akt,
FAK, and Src in the migration and invasion processes of colorectal
adenocarcinoma cells. We have shown that FAK is indispensable for
cell migration, and in addition, we established a novel function of
Akt as a direct regulator of the FAK function. This Akt promigratory
role is partly dependent on active Src. Besides migration, FAK, Akt,
Src, and PI3 kinases are also involved in invasion, but their interac-
tions in this process are less clear and will certainly need additional
evaluation. What can be suggested based on our presented results is
that the Akt-1 isoform may not function as a modulator of MMP-9
activity in colorectal cancer cells. In conclusion, our findings place
Figure 6. MMP-9 enzymatic activity is attenuated in the absence of
FAK in colorectal cancer cells. Conditioned culture media of differ-
ent cell lines and SW620 clones were tested for activity of MMP-9
in gelatin zymography enzymatic assays. MMP-2 activity was in-
cluded as a loading control because it never changed its level under
any conditions. (A) Comparison of MMP activities in the indicated
cells lines. (B) Zymography of conditional media of SW620/GIPZ
versus SW620shFAK#5 cells incubated in the absence or presence
of Akt, Src, or PI3 kinase inhibitors. In the statistical analysis of the
densitometric data provided (n = 3 for each, *P < .01 and **P <
.001), outcomes of all the indicated treatments plus the DMSO-
treated shFAK#5 cells were normalized to the SW620/GIPZ cells
treated with a vehicle only (DMSO). (C) MMP-9 activities in condi-
tional media produced by SW620/GIPZ and SW620shFAK#5 cells
expressing adenoviral iAkt inducible by HXT incubated in the pres-
ence or absence of SU6656 inhibitor. Data obtained from all the in-
dicated treatments and from the DMSO-treated SW620shFAK#5
cells were normalized to SW620/GIPZ cells treated with DMSO only
(n = 3 for each, **P < .001).
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FAK downstream of the PI3 kinase/Akt signaling pathway. Because
this pathway is very often dysregulated in various types of human
cancer [41,42], our results imply FAK as a potentially important par-
ticipant in tumor initiation or progression.
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